Market Overview

SGLT-2 Inhibitor Market Size is projected to achieve a value of USD 10.21 Billion in 2023, with a linear behavior in the market growth it is forecasted to achieve a value of USD 20.65 Billion by 2033 with a CAGR of 8.5% during the forecast period 2024-2033.

Type 2 diabetes is treated with a class of drugs called sodium-glucose co-transporter 2 (SGLT-2) inhibitors. By inhibiting the kidneys' SGLT-2 protein, they decrease the absorption of glucose and increase its excretion in urine. By lowering blood sugar levels, this process helps with diabetes management. SGLT-2 inhibitors have also been linked to cardiovascular benefits and may aid in weight loss. But occasionally, they can raise the risk of vaginal yeast infections and urinary tract infections.

            Get more in-depth information of this reports – Request Free Sample

The primary factor propelling the SGLT-2 inhibitor market is its effectiveness in the treatment of type 2 diabetes. Due to their special advantages, which include lowering cardiovascular risks and promoting weight loss, these drugs are gaining popularity among patients and medical professionals looking to treat diabetes patients completely. Further propelling market expansion are their ability to complement current treatment regimens and ease of oral administration. The growing demand for and use of SGLT-2 inhibitors in the pharmaceutical industry is partly due to the rising incidence of diabetes worldwide.

Market Scope

SGLT-2 Inhibitor Industry:  Dynamics & Restrains

Market Drivers

Additional positive Cardiovascular Benefits - The SGLT-2 inhibitor Market inhibitors is mostly driven by the additional beneficial cardiovascular effects that are linked to these drugs. Research has demonstrated that these drugs are more than just glucose-lowering agents, with decreased risks of heart failure, cardiovascular events, and possible protective effects on the kidney. Healthcare practitioners looking for all-inclusive treatments for diabetic patients at risk of cardiovascular issues are drawn to this extended therapeutic profile, which has completely changed ideas about how patients should be treated. In addition to boosting market expansion and establishing SGLT-2 inhibitors as essential components in diabetes management with additional cardiovascular advantages, the promise of simultaneously addressing numerous health concerns raises the appeal and adoption rates of these drugs.

Effectiveness in Glycemic Control - The commercial expansion of SGLT-2 inhibitors is mostly driven by how well they manage blood sugar levels. By preventing the kidneys from reabsorbing glucose, these drugs provide a unique mechanism that lowers blood sugar. Healthcare professionals looking for strong glucose-lowering drugs are drawn to their effectiveness, which is frequently on par with or better than conventional diabetes therapies. Their usefulness is further increased by their capacity to supplement current treatments or offer a substitute for patients who are intolerant to other drugs. Because of its remarkable ability to control blood sugar levels, SGLT-2 inhibitors are fundamental to diabetes treatment plans, which greatly contributes to their market domination and ongoing success.

Market Restrains

Side Effects and Safety Concerns - The SGLT-2 inhibitor Market has been severely limited by side effects and safety concerns. Patients and healthcare professionals are being cautious due to adverse effects such as vaginal mycotic infections, urinary tract infections, and the possibility of diabetic ketoacidosis. These safety concerns restrict their use despite their effectiveness, particularly in specific patient groups or those with predisposing factors. Prescription patterns and patient acceptance are further impacted by regulatory monitoring and warnings, which makes patients more cautious while using SGLT-2 inhibitors. To relieve these constraints and guarantee broader market adoption, it is imperative to address these worries through improved education, more transparent risk communication, and ongoing research to reduce adverse consequences.

SGLT-2 Inhibitor Segmentation

Market- By Type Analysis

By Type, the SGLT-2 inhibitor Market is Categories into Canagliflozin, Dapagliflozin, Empagliflozin, Remogliflozin. The Canagliflozin segment accounts for the largest share of around 35% in 2022.

Canagliflozin introduced first reliable clinical evidence for its safety and effectiveness for the treatment of chronic renal disease, heart failure, and type 2 diabetes, broad label.

The following segments are part of an in-depth analysis of the global market for Parkinson's disease therapies:

Would you like this research report to be customized to meet your needs?

The information needed to assist you in making wise business decisions

will be covered by our research team – Customize this report

SGLT-2 Inhibitor Market Industry: Regional Analysis

North America Market Forecast

North America dominate the SGLT-2 inhibitor Market with the highest revenue generating market with share of more than 47%. The SGLT-2 inhibitor market has expanded as a result of advantageous reimbursement policies, a big population of diabetics, and raised awareness, also AstraZeneca, Johnson & Johnson, and other businesses are well-represented in this market.

Europe Market Statistics

Europe is the second-largest market for SGLT-2 inhibitor. European nations have differing adoption rates. Some nations, like Germany, France, and the UK, have welcomed SGLT-2 inhibitors because of how well they work to treat diabetes. However, differences in pricing regulations and healthcare systems among European countries have resulted in differences in market penetration.

APAC Market Forecasts

Asia Pacific is expected to be the fastest-growing market for SGLT-2 inhibitor during the forecast period. SGLT-2 inhibitors are becoming more and more widespread in nations like South Korea, Japan, and Australia. Because of the country's high rate of diabetes and its healthcare providers' proactive adoption of innovative treatments, Japan has proven to be a particularly important market. Although the industry is expanding in other regions of Asia, variables including the state of the healthcare system and economic growth may have an impact.

Competitive Analysis

The SGLT-2 inhibitor Market is dominated by a few large companies, such as

·         AstraZeneca

·         Boehringer Ingelheim

·         Bristol-Myers Squibb

·         Daiichi Sankyo

·         Eli Lilly and Company

·         GlaxoSmithKline

·         Johnson & Johnson

·         Merck & Co.

·         Novo Nordisk

·         Sanofi

There are some of the key trends that are shaping the competitive landscape of the SGLT-2 inhibitor Market.

·         October 2023, AstraZeneca announced that Farxiga (dapagliflozin) has been approved by the European Medicines Agency (EMA) for the treatment of chronic kidney disease (CKD) in adults at risk of progression to end-stage kidney disease (ESKD) and cardiovascular events, regardless of their diabetes status.

·         February 2022, The USFDA approved Boehringer Ingelheim's use of Jardiance (empagliflozin) for additional purposes to reduce hospitalization and death risk in patients with heart failure and low ejection fraction, as well as in those with type 2 diabetes with prior cardiovascular illness.